



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

09 July 2021
EMA/222638/2021
EMA/H/C/001018

Public statement

Ribavirin Teva

Withdrawal of the marketing authorisation in the European Union

On 22 June 2021, the European Commission withdrew the marketing authorisation for Ribavirin Teva (ribavirin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva B.V., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Ribavirin Teva was granted marketing authorisation in the EU on 31 March 2009 for the treatment of chronic hepatitis C. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014.

Ribavirin Teva is a generic medicine of Rebetol.

The European Public Assessment Report (EPAR) for Ribavirin Teva will be updated to indicate that the marketing authorisation is no longer valid.

